Can anyone access this paper? Or the first page anyway? Thanks!

[TaraJR]

Can anyone access any of this new paper? Oh how I hate paywalls. I can't even get the first page, as it seems to say is available. It may have something interesting in there ...

liebertpub.com/doi/fpi/10.1...

[arTistapple]

Well the headline is certainly interesting. I hope someone can get the whole paper to display.

[JGBH]

I can’t access it either… sorry. Hate Paywalls too.

[Star13]

it’s under a subscription and copyrighted!

[Star13]

I managed to get this exert only:

Reasons may include inappropriate dosing, incorrect diagnosis, relative tissue deficiency of T3 from impaired peripheral conversion of T4 to T3, and alterations of genes involved in thyroid hormone transport and metabolism (3).

[annabianca]

According to the index, this article is a review of another article

Why Do So Many Patients Receiving Levothyroxine Treatment for Hypothyroidism Have Persistent Symptoms?

Giorgio Grani

Review of: Hidalgo J, Vallejo BA, Jacome CS, Ayala IN, Cordova S, Duran M, Golembiewski E, Toro-Tobon D, Brito JP 2023 Real practice assessment of persistent symptoms after initiation of levothyroxine. Endocr Pract. Epub 2023 Oct 30:S1530-891(23)00730-9. PMID: 37913925.

There isn't a full copy available, but the summary is here

sciencedirect.com/science/a...

[humanbean in reply to annabianca]

I found the abstract of that paper being reviewed here :

europepmc.org/article/MED/3...

Abstract

Objective

Levothyroxine (LT4) is the standard treatment for hypothyroidism. However, certain patients experience persistent symptoms even after achieving euthyroid status with LT4 therapy. We aimed to determine the frequency of persistent or new symptoms in patients with hypothyroidism after initiating LT4.

Methods

This retrospective study included patients with hypothyroidism who started on LT4 between January 2017 and December 2019 at Mayo Clinic in Rochester, Minnesota, USA. Five hundred patient charts were randomly selected for review. Patients with at least 1 documented follow-up encounter after LT4 initiation were evaluated for ≤3 follow-up visits regarding their biochemical status and symptoms.

Results

We included 356 patients, a majority of whom were female (66.6%), white (92.3%), and obese (71.9%), with an average age of 59.5 years. At the baseline visit, approximately one-half of the patients (177/356, 47.7%) reported hypothyroid symptoms, with fatigue being the most common symptom. During the follow-up periods, we observed that 17.8% (28/157), 17.9% (19/106), and 19.3% (11/57) of patients had normal thyroid stimulating hormone (TSH) values but persistent symptoms, while 12.3% (19/156), 19.9% (16/107), and 8.9% (5/56) had normal TSH values but new symptoms. Overall, during each respective follow-up period, 26.7% (42/157), 27.3% (29/106), and 28% (16/57) of patients experienced persistent or new symptoms alongside normal TSH values, with fatigue being the most constant symptom.

Conclusion

Our findings indicate that approximately 1 in every 4 patients with hypothyroidism receiving LT4 therapy and achieving normal TSH levels experience persistent or new hypothyroid symptoms. The cause of these symptoms remains unclear, emphasizing the need for a better understanding of their underlying causes and the development of effective management strategies.

Full text links

Read article at publisher's site: doi.org/10.1016/j.eprac.202...

[arTistapple in reply to humanbean]

I get the feeling this information has been around in one form or another for a while. It’s surely been being ignored purposefully. The references contained a number of papers which Perros has taken part in, whilst nothing of his looks like it is contained in this paper. If that’s the case that is a good thing for a number of reasons I can think of. The main one being (hopefully) that his work was not worth mentioning.

[arTistapple in reply to annabianca]

Well that covers the 20% we are always referring to on the forum.

[SlowDragon Administrator]

appears to only have been published Dec 2023